TSX:ONC 0.86 CAD +0.00 +0% Volume: 244,600 April 27, 2015
NASDAQ:ONCY 0.70 USD +0.00 +0% Volume: 854,800 April 27, 2015

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

April 20, 2015 Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual Meeting
April 17, 2015 Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Malignant Gliomas
April 15, 2015 Oncolytics Biotech® Inc. Presents at UK Immuno-oncology Meeting
Sign up to receive e-mail updates *